Carlyle Group Files SC 13D/A Amendment for Soleno Therapeutics

TL;DR

Carlyle Group just updated its stake in Soleno Therapeutics (SLNO) via a 13D/A filing.

AI Summary

On October 15, 2024, Carlyle Group Inc. and its affiliates, including Abingworth Bioventures VII LP, filed an SC 13D/A amendment regarding their holdings in Soleno Therapeutics Inc. The filing indicates a change in beneficial ownership, though specific new percentage or dollar amounts are not detailed in this excerpt.

Why It Matters

This filing signals a potential shift in control or significant investment activity by a major financial player in Soleno Therapeutics, which could impact the company's strategic direction and stock performance.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can indicate significant strategic moves by large investors, potentially leading to volatility.

Key Numbers

• 20241015 — Filing Date (Date of the SC 13D/A amendment)

Key Players & Entities

• Carlyle Group Inc. (company) — Filing entity
• Abingworth Bioventures VII LP (company) — Affiliated entity
• Soleno Therapeutics Inc (company) — Subject company
• 0001193125-24-237617 (filing_id) — Accession number

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
• $52.00 — October 9, 2024 255,963 $ 50.355 to $52.00 $ 51.0507 October 10, 2024 182,48
• $51.76 — ctober 10, 2024 182,489 $ 49.585 to $51.76 $ 50.6347 October 11, 2024 344,52
• $54.815 — October 11, 2024 344,527 $ 50.85 to $54.815 $ 54.0930 (d) None. (e) Not appl

Filing Documents

• d726271dsc13da.htm (SC 13D/A) — 182KB
• 0001193125-24-237617.txt ( ) — 185KB

of the Schedule 13D is hereby amended and restated in its entirety as follows

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows: (a) (b) The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 40,108,265 shares of Common Stock, which includes (i) 38,871,594 shares of Common Stock outstanding as of August 2, 2024, as disclosed in the Issuers quarterly report on Form 10-Q filed on August 7, 2024, (ii) 22,913 shares of Common Stock underlying stock options exercisable within 60 days as of the date hereof and (iii) 1,213,758 shares of Common Stock underlying the Prefunded Warrants, all of which are currently exercisable. Reporting Person Amount beneficially owned Percent of class Sole power to vote or to direct the vote Shared power to vote or to direct the vote Sole power to dispose or to direct the disposition Shared power to dispose or to direct the disposition The Carlyle Group Inc. 2,468,099 6.2 % 0 2,468,099 0 2,468,099 Carlyle Holdings I GP Inc. 2,468,099 6.2 % 0 2,468,099 0 2,468,099 Carlyle Holdings I GP Sub L.L.C. 2,468,099 6.2 % 0 2,468,099 0 2,468,099 Carlyle Holdings I L.P. 2,468,099 6.2 % 0 2,468,099 0 2,468,099 CG Subsidiary Holdings L.L.C. 2,468,099 6.2 % 0 2,468,099 0 2,468,099 TC Group, L.L.C. 2,468,099 6.2 % 0 2,468,099 0 2,468,099 Carlyle Investment Management L.L.C. 2,468,099 6.2 % 0 2,468,099 0 2,468,099 Carlyle Genesis UK LLC 2,468,099 6.2 % 0 2,468,099 0 2,468,099 Abingworth LLP 2,468,099 6.2 % 0 2

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : October 15, 2024 The Carlyle Group Inc. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Carlyle Holdings I GP Inc. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director and Chief Financial Officer Carlyle Holdings I GP Sub L.L.C. By: Carlyle Holdings I GP Inc., its sole member By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director and Chief Financial Officer Carlyle Holdings I L.P. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director CG Subsidiary Holdings L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director TC Group, L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director CUSIP No. 834203200 13D Page 15 of 15 pages Carlyle Investment Management L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Carlyle Genesis UK LLC By: Carlyle Investment Management L.L.C., its sole member By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Abingworth LLP By: /s/ John Heard Name: John Heard Title: Authorized Signatory Abingworth Bioventures VII LP By: /s/ John Heard Name: John Heard Title: Authorized Signatory